Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability

INTRODUCTION: Little data is available on patients with advanced non-squamous NSCLC treated with erlotinib specifically after failure of first-line pemetrexed-containing chemotherapy. We assessed the effectiveness, safety and tolerability of erlotinib in a real-world setting. METHODS: Prospective si...

Descripción completa

Detalles Bibliográficos
Autores principales: Germonpré, Paul, Van den Wyngaert, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459587/
https://www.ncbi.nlm.nih.gov/pubmed/30973926
http://dx.doi.org/10.1371/journal.pone.0215135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459587/
https://www.ncbi.nlm.nih.gov/pubmed/30973926
http://dx.doi.org/10.1371/journal.pone.0215135

Ejemplares similares